Table 3.
Clinical outcome according to re-TUR status and the presence or absence of muscle in the specimen of the first TUR
| Variable | No muscle, no reTUR (%) | No muscle, reTUR (%) | Muscle, no reTUR (%) | Muscle, reTUR (%) | Unknown (%) | All Patients (%) |
|---|---|---|---|---|---|---|
|
| ||||||
| N | 130 | 276 | 1092 | 624 | 329 | 2451 |
|
| ||||||
| Recurrence | ||||||
| No | 52 (40.0) | 115 (41.7) | 561 (51.4) | 281 (45.0) | 198 (60.2) | 1207 (49.3) |
| Yes | 60 (60.0) | 161 (58.3) | 531 (48.6) | 343 (55.0) | 131 (39.8) | 1244 (50.7) |
|
| ||||||
| Progression | ||||||
| No | 102 (78.5) | 238 (86.2) | 871 (79.8) | 504 (80.8) | 271 (82.4) | 1986 (81.0) |
| Yes | 28 (21.5) | 38 (13.8) | 221 (20.2) | 120 (19.2) | 58 (17.6) | 465 (19.0) |
|
| ||||||
| Cancer specific mortality | ||||||
| No | 115 (88.5) | 257 (93.1) | 998 (91.4) | 563 (90.2) | 297 (90.3) | 2230 (91.0) |
| Yes | 15 (11.5) | 19 (6.9) | 94 (8.6) | 61 (9.8) | 32 (9.7) | 221 (9.0) |
|
| ||||||
| Overall Survival | ||||||
| Alive | 89 (68.5) | 219 (79.4) | 812 (74.4) | 485 (77.7) | 250 (76.0) | 1855 (75.7) |
| Dead | 41 (31.5) | 57 (20.6) | 280 (25.6) | 139 (22.3) | 79 (24.0) | 596 (24.3) |